Focal segmental glomerulosclerosis

This early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care,…

This study tests a drug called sparsentan for people who have protein in their urine after a kidney transplant due to IgA nephropathy or FSGS. About 20 adults will take the drug once daily for 36 weeks to see if it safely reduces protein levels and protects kidney function. The g…

This study tests an experimental drug called APL2 for people with a kidney disease called FSGS. The goal is to see if APL2 can reduce protein in the urine, a sign of kidney damage. The trial has two parts: first, adults will receive APL2 openly; then, both adults and adolescents …

This phase 2 study tests the drug atrasentan in 103 adults with various kidney diseases that cause protein leakage, including IgA nephropathy and FSGS. Participants take a daily tablet to see if it reduces protein in urine, a sign of kidney damage. The goal is to find a new way t…

This study tests whether a lower dose of the steroid prednisone can treat relapses of nephrotic syndrome in children as effectively as the standard dose. Fifty children aged 1 to 18 with active relapses will be randomly assigned to either the reduced-dose or standard-dose regimen…

This study aims to find the genetic causes of kidney diseases like FSGS and nephrotic syndrome. Researchers will collect saliva and urine samples from up to 2,050 participants, including patients and their family members, as well as healthy volunteers. The goal is to understand w…

This study follows over 3,000 Black people with HIV in the UK to understand how genes and lifestyle affect their risk for kidney disease, heart disease, diabetes, and obesity. Researchers collect health data and blood/urine samples to find genetic markers that predict these condi…